Big Pharma’s about to lose $200 billion in drug revenue — and the race to replace it is reshaping biotech worldwide.
On this episode, Robert Darwin, Senior Partner at global law firm Sidley Austin, joins us to explore:
Why pharma’s writing massive M&A checks again
How China is emerging as a leading hub for drug innovation
Europe’s strengths—and where it still needs to catch up
What’s stalled IPO markets — and what could kickstart them again
Where the new biotech funding is really coming from (it might surprise you)
Plus: Robert offers his straightforward insights on FDA developments, pricing politics, and why today’s science feels straight out of “Star Trek.”
If you’re in biotech, finance, or just curious about the industry’s future, this conversation is for you.
🎧 Hit play now and stay ahead of the curve.
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com
The Breakfast Club
The World's Most Dangerous Morning Show, The Breakfast Club, With DJ Envy, Jess Hilarious, And Charlamagne Tha God!